Peter Greenleaf

Peter Greenleaf

Président chez
Maryland Venture Fund

Fortune : 29 M $ au 31/05/2026

56 ans
Health Technology
Finance
Commercial Services

Profil

Peter S.
Greenleaf
is Chairman at Maryland Venture Fund, Chairman at Pelthos Therapeutics, Inc., Chairman at Revolo Biotherapeutics Ltd. since 2020, and holds an Advisory role at Petrichor Healthcare Capital Management LP.
Former roles include President, Chief Executive Officer & Director at Histogenics Corp.
(2013–2014); Chairman & Chief Executive Officer at Sucampo Pharmaceuticals LLC (2016–2018);.
President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. (2019–2026); Chairman at BioDelivery Sciences International, Inc. (2018–2022); Independent Director at Antares Pharma, Inc. (2018–2022); Independent Director at Mast Therapeutics, Inc.; Director at Oldtech, Inc.; Director at Kiora Pharmaceuticals, Inc. (2018–2020); Director at Biotechnology Innovation Organization; Director at Melinta Subsidiary Corp.; Director at Tech Council of Maryland, Inc.; Director at LigoCyte Pharmaceuticals, Inc.; Independent Director at Mirna Therapeutics, Inc.; Director at Corridor Pharmaceuticals, Inc.; Director at Savara, Inc.; Director at OS Therapies, Inc.; Director at Avalo Therapeutics, Inc. (2019–2020); Director at Pharmaceutical Research & Manufacturers of America; Director at ValenzaBio, Inc.; Senior Vice President-Remicade Franchise at Centocor, Inc. (1998–2006); President at MedImmune LLC (2006–2013); Principal at US Healthcare, Inc.; Principal at Hallmark Cards, Inc.; President at MedImmune Ventures, Inc. (2010–2013); Principal at Roche Diagnostics Corp.
(1996–1998); Trustee at The University of Maryland Baltimore Foundation, Inc.; District Manager at Boehringer Mannheim GmbH (1996–1998); President at AstraZeneca PLC (2006–2013).
Education includes an MBA from St. Joseph's University and undergraduate studies at Western Connecticut State University.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
02/03/2026 1 840 379 ( 1,43 % ) 28 M $ 31/05/2026
0,71 %
02/04/2026 24 681 ( 0,71 % ) 653 306 $ 31/05/2026

Dernières actualités sur Peter Greenleaf

Postes actifs de Peter Greenleaf

SociétésPosteDébut
Président -
Président 17/12/2020
Consultant / Advisor -

Anciens postes connus de Peter Greenleaf

SociétésPosteFin
AURINIA PHARMACEUTICALS INC. Directeur Général 23/03/2026
ANTARES PHARMA, INC. Directeur/Membre du Conseil 24/05/2022
BIODELIVERY SCIENCES INTERNATIONAL, INC. Président 22/03/2022
AVALO THERAPEUTICS, INC. Directeur Général 15/04/2019
KIORA PHARMACEUTICALS, INC. Directeur/Membre du Conseil 03/01/2020
Voir l'expérience en détail de Peter Greenleaf

Formation de Peter Greenleaf

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

69

Relations au 1er degré

33

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées33

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Miscellaneous

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Boehringer Mannheim GmbH

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Peter Greenleaf
-40% : Prolongation exceptionnelle ➤➤➤➤
j
:
:
PROFITEZ-EN MAINTENANT
🔇